ArticleAging2012
How to save Medicare: the anti-aging remedy.
Article in Aging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Compression of morbidity by interventions that steepen the survival curve.Nature communications · 2025Article
- Review
- Quo Vadis, Dottore? Religious, Philosophical and Medical Perspectives on the Quest for Immortality.Journal of religion and health · 2022Article
- The goal of geroscience is life extension.Oncotarget · 2021Article
- Article
- Rapamycin for longevity: opinion article.Aging · 2019Article
- Quality of life after staged bilateral total knee arthroplasty: a minimum five-year follow-up study of seventy-eight patients.International orthopaedics · 2019Article
- Functional aging in health and heart failure: the COmPLETE Study.BMC cardiovascular disorders · 2019Article
- Disease or not, aging is easily treatable.Aging · 2018Article
- mTORC1 as the main gateway to autophagy.Essays in biochemistry · 2017Review
- Implementation of longevity-promoting supplements and medications in public health practice: achievements, challenges and future perspectives.Journal of translational medicine · 2017Review
- From rapalogs to anti-aging formula.Oncotarget · 2017Review
- Self-motivated and stress-response performance assays in mice are age-dependent.Experimental gerontology · 2017Article
- Age, serum 25-hydroxyvitamin D and vitamin D receptor (VDR) expression and function in peripheral blood mononuclear cells.Oncotarget · 2016Article
- Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity.The Journal of physiology · 2016Review
- Article
- Rejuvenating immunity: "anti-aging drug today" eight years later.Oncotarget · 2015Article
- The aging-disease false dichotomy: understanding senescence as pathology.Frontiers in genetics · 2015Review
- Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Oncotarget · 2014Article
- Gerosuppression in confluent cells.Aging · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unprecedented progress in aging research has revealed that rapamycin, a clinically approved drug, is actually an anti-aging agent, which potentially could be employed to delay age-related diseases, thus extending healthy life span. The possibility of preventing diseases by staying young is remarkable in itself. At the same time this advance could save Medicare as we know it. Here I discuss how anti-aging interventions could solve otherwise intractable political problems without tax increases or curtailment of health care benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.